MarketCap
Facebook
X
Telegram
Alkermes plc Cash Conversion Cycle | ALKS
Annual Cash Conversion Cycle Alkermes plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 299 | 276 | 262 | 302 | 253 | 224 | 179 | 205 | 183 | 140 | 93 | 129 | 133 | 151 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 302 | 93 | 202 |
Quarterly Cash Conversion Cycle Alkermes plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 237 | 261 | 325 | 291 | 273 | 278 | 347 | 294 | 265 | 235 | 273 | 228 | 236 | 227 | 321 | 320 | 315 | 272 | 276 | 252 | 280 | 254 | 292 | 215 | 198 | 223 | 203 | 122 | 168 | 173 | 200 | 166 | 178 | 122 | 149 | 156 | 155 | 112 | 87.5 | - | 91.8 | 75.9 | 85.9 | - | 82.7 | 83.7 | 83.1 | - | 80.7 | 78 | 90.2 | - | 87.6 | 83.8 | 70.9 | 82.1 | 81.6 | 39.3 | - | 73 | 32.4 | 35 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 347 | 32.4 | 181 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M |  USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-4.37 K | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
AbbVie
ABBV
|
284 | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
33.4 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Axon Enterprise
AXON
|
64.5 | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
58.6 | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-24.8 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
Dynavax Technologies Corporation
DVAX
|
459 | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
31.7 | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
217 | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
25.8 | - | -33.86 % | $ 61.2 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
66.2 | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
88.2 | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
729 | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
Sage Therapeutics
SAGE
|
408 | - | - | $ 527 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
19.2 | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
252 | - | - | $ 121 M | USA |
 |
Eli Lilly and Company
LLY
|
291 | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
Compugen Ltd.
CGEN
|
-82.7 | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Crinetics Pharmaceuticals
CRNX
|
-4.27 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
48.4 | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-284 | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
63.2 | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
-307 | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
-44.1 | $ 248.62 | -0.88 % | $ 96.7 B | USA |